Fig. 2From: Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaSurvival curves. a PFS, efficacy population (n = 27). b OS, efficacy population (n = 27). Including data after end of study. c Kaplan-Meier plot with separation for Cmax (ng/mL). PFS according to the optimal cutpoint at 270 ng/mL. Log-rank, p = 0.02 (exploratory analysis)Back to article page